Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep 28;19(9):jjaf154.
doi: 10.1093/ecco-jcc/jjaf154.

Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study

Chandni Radia  1   2 , Yaa Danso  3 , Susan Ritchie  4 , Melissa Hale  5 , Alexander T Elford  6   7 , Chirag Patel  8 , Lucy Hicks  9 , Sonia Kalyanji  10 , Chaonan Dong  11 , Katie Yeung  12 , Jie Han Yeo  13 , Mohammed Allah-Ditta  14 , Maria Bishara  15 , Karishma Sethi-Arora  16 , Lushen Pillay  17 , Emma L Johnston  18 , Ruth Rudling  19 , Fiona Rees  20 , Philip Harvey  21 , Hannah Trodden-Mittnacht  22 , Emma Davis  23 , Aileen Fraser  24   25 , Nitish Jivan Sawan  26 , Muhammad Azhar Hussain  27 , Roisin Campbell  28 , Becky George  29 , Megan Rawcliffe  5 , Xin Yi Choon  8 , Krishna Shah  3 , Dania Al-Zarrad  12 , Jennifer Toft  13 , Puneet Chhabra  14 , Nick Burr  19   20 , Alice Hewitt  22 , Rohith Kumar  27 , Sara McCartney  13 , Konstantina Rosiou  22 , Anjan Dhar  4 , Charlie W Lees  6   30 , Christopher A Lamb  11   31 , Ally Speight  11 , Tariq Ahmad  15   32 , Jimmy Limdi  16 , Tim Raine  17 , Alissa Walsh  23 , Rachel Cooney  27 , Paul Harrow  13 , Kamal Patel  10 , Mark Samaan  8 , Polychronis Pavlidis  1 , Alexandra Kent  1 , Christian Selinger  22   33 , Klaartje Bel Kok  3
Affiliations
Multicenter Study

Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study

Chandni Radia et al. J Crohns Colitis. .

Abstract

Background and aims: Janus kinase inhibitors (JAKi) provide effective treatment for ulcerative colitis (UC), but inadequate response (IR) or intolerance occurs frequently. This study aimed to assess the effectiveness of a second JAKi in a real-world UC cohort.

Methods: A retrospective multicenter cohort study encompassing 19 UK hospitals was undertaken. Primary outcome was clinical remission (Simple Clinical Colitis Activity Index/partial Mayo Score ≤ 1) at weeks 8 and 24, based on available assessments. Biochemical (CRP ≤ 5mg/L and fecal calprotectin ≤ 200µg/g) and endoscopic (Ulcerative Colitis Endoscopic Index of Severity/Mayo Endoscopic Subscore ≤ 1) remission were also assessed.

Results: A total of 131 patients with active UC were included. The majority (60%) had exposure to ≥3 advanced therapies and 50% required corticosteroids at induction. Clinical remission rates were 59% and 51% at weeks 8 and 24. Biochemical and endoscopic remission rates were 61% and 60% at week 8, and 47% and 32% at week 24. All disease activity parameters significantly reduced by week 8 (P < .001). At week 24 no difference was detected in clinical remission rates between those with primary non-response (42%) or secondary loss of response (52%) to their first JAKi (P = .518). Clinical remission did not differ between upadacitinib (54%) and filgotinib (36%), P = .253. Adverse events occurred in 27% of patients, and serious adverse events in 8%.

Conclusions: In this highly refractory cohort with active UC a second JAKi effectively achieved remission following IR to first JAKi. Type of first JAKi failure did not appear to influence clinical remission. No new safety signals were found.

Keywords: Janus kinase inhibitors; primary non-response; secondary loss of response; ulcerative colitis.

PubMed Disclaimer

Publication types